Innoviva Number of Employees 2010-2024 | INVA

Innoviva number of employees from 2010 to 2024. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Innoviva Annual Employee Count
2024 127
2023 112
2022 101
2021 5
2020 5
2019 6
2018 6
2017 12
2016 14
2015 13
2014 10
2013 241
2012 226
2011 222
2010 193
2009 194
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $1.173B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) US $780.574B 59.86
Johnson & Johnson (JNJ) US $375.636B 15.53
AbbVie (ABBV) US $351.089B 19.33
Novo Nordisk (NVO) DK $310.672B 21.04
Roche Holding AG (RHHBY) CH $262.006B 0.00
Novartis AG (NVS) CH $241.429B 13.79
Merck (MRK) US $209.760B 10.68
Sanofi (SNY) FR $140.056B 13.39
Pfizer (PFE) US $137.249B 7.54
Bayer (BAYRY) DE $26.486B 4.92